White | Black | Asian/Other | ||
---|---|---|---|---|
N = 117 | N = 21 | N = 21 | p-value* | |
Age, median (IQR) | 11.6 | 13.0 | 10.6 | 0.20 |
(7.2–14.6) | (9.3–16.0) | (5.9–14.3) | ||
Male sex, n (%) | 14 (12%) | 6 (29%) | 7 (33%) | 0.02 |
Hispanic ethnicity | 3 (3%) | 0 (0%) | 4 (19%) | 0.01 |
Public insurance | 47 (40%) | 15 (71%) | 12 (57%) | 0.02 |
Incident diagnosis (< 6 months) | 37 (32%) | 12 (57%) | 9 (43%) | 0.08 |
Rheumatoid factor positive | 13 (11%) | 11 (52%) | 5 (24%) | < 0.01 |
Non-biologic DMARD use | 61 (52%) | 12 (57%) | 13 (62%) | 0.71 |
Biologic use | 48 (41%) | 6 (29%) | 6 (29%) | 0.43 |
cJADAS-10, median (IQR) | 5.5 | 13.6 | 6.2 | 0.02 |
(0.5–13.6) | (9.5–19.0) | (0.7–17.0) | ||
Physician global assessment | 1.0 | 4.0 | 1.5 | < 0.01 |
(0.0–3.0) | (2.0–5.0) | (0.0–4.5) | ||
Patient/parent global assessment | 2.0 | 4.4 | 2.8 | 0.06 |
(0.4–4.0) | (2.1–6.8) | (0.3–4.9) | ||
Joint count | 0.0 | 5.0 | 1.0 | 0.06 |
(0.0–6.0) | (1.0–9.0) | (0.0–5.5) | ||
Pain | 1.9 | 6.3 | 3.2 | 0.01 |
(0.5–4.8) | (3.1–7.3) | (0.4–4.8) | ||
PROMIS® upper extremity | 49.0 | 31.8 | 47.0 | 0.05 |
(34.1–56.7) | (26.1–55.9) | (34.1–56.7) | ||
PROMIS® mobility | 48.0 | 35.0 | 48.0 | 0.02 |
(40.0–58.5) | (29.2–51.0) | (32.0–56.0) |